Karilizumab is an anti-cancer treatment drug for anti-PD-1 immunotherapy, mainly for the treatment of advanced lung cancer, liver cancer, esophageal cancer and Hodgkin’s lymphoma, with good therapeutic effect but with side effects, so it should be taken under the guidance of a professional physician. Karilizumab shows stronger tumor suppression efficacy compared with similar drugs, and the actual anti-tumor effect is better. In the treatment of typical Hodgkin’s lymphoma and metastatic nasopharyngeal carcinoma, which are seizures or not easily treated, as well as terminal liver cancer, karilizumab has shown good therapeutic effects. And in terms of safety, carrilizumab has low immunity-related side effects and morbidity for patients. Therefore, karilizumab not only improves the balance of efficacy and toxic side effects, but also reduces side effects while maintaining the efficacy of the drug compared to existing drugs of the same type, enabling a certain extension of the survival period and a better quality of life. As a PD-1 immunotherapy drug, the adverse reactions of karilizumab are lower than those of conventional chemotherapy, but be alert to rare and serious immune-related adverse reactions, the incidence of which can be up to 10%. When taking karilizumab, capillary hyperplasia, anemia, fever, malaise, and some patients may also experience side effects such as proteinuria, hypothyroidism, and decreased appetite. When patients develop grade II or higher immune-associated pneumonia, hepatitis, nephritis, enteritis and myocarditis, the drug should be discontinued promptly and permanently discontinued. Therefore, when using carrilizumab, it should be done under the guidance of a doctor, and the adverse reactions to the drug should be observed at all times during the administration of the drug, and when symptoms appear, a doctor should be consulted promptly to be alert to the possibility of serious adverse reactions and to give timely intervention.